vs
德康医疗（DXCM）与Masco（MAS）财务数据对比。点击上方公司名可切换其他公司
Masco的季度营收约是德康医疗的1.5倍（$1.9B vs $1.3B），德康医疗净利率更高（21.2% vs 11.9%，领先9.3%），德康医疗同比增速更快（21.6% vs 6.5%），过去两年德康医疗的营收复合增速更高（12.0% vs -4.2%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
DXCM vs MAS — 直观对比
营收规模更大
MAS
是对方的1.5倍
$1.3B
营收增速更快
DXCM
高出15.1%
6.5%
净利率更高
DXCM
高出9.3%
11.9%
两年增速更快
DXCM
近两年复合增速
-4.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.9B |
| 净利润 | $267.3M | $228.0M |
| 毛利率 | 62.9% | 35.8% |
| 营业利润率 | 25.6% | 16.5% |
| 净利率 | 21.2% | 11.9% |
| 营收同比 | 21.6% | 6.5% |
| 净利润同比 | 153.6% | 14.5% |
| 每股收益（稀释后） | $0.67 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMMAS
| Q1 26 | $1.3B | $1.9B | ||
| Q4 25 | $1.3B | $1.8B | ||
| Q3 25 | $1.2B | $1.9B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.1B | $1.8B | ||
| Q3 24 | $994.2M | $2.0B | ||
| Q2 24 | $1.0B | $2.1B |
净利润DXCMMAS
| Q1 26 | $267.3M | $228.0M | ||
| Q4 25 | $267.3M | $165.0M | ||
| Q3 25 | $283.8M | $189.0M | ||
| Q2 25 | $179.8M | $270.0M | ||
| Q1 25 | $105.4M | $186.0M | ||
| Q4 24 | $151.7M | $182.0M | ||
| Q3 24 | $134.6M | $167.0M | ||
| Q2 24 | $143.5M | $258.0M |
毛利率DXCMMAS
| Q1 26 | 62.9% | 35.8% | ||
| Q4 25 | 62.9% | 33.9% | ||
| Q3 25 | 60.5% | 34.2% | ||
| Q2 25 | 59.5% | 37.6% | ||
| Q1 25 | 56.9% | 35.8% | ||
| Q4 24 | 58.9% | 34.8% | ||
| Q3 24 | 59.7% | 36.6% | ||
| Q2 24 | 62.4% | 37.5% |
营业利润率DXCMMAS
| Q1 26 | 25.6% | 16.5% | ||
| Q4 25 | 25.6% | 13.8% | ||
| Q3 25 | 20.1% | 15.8% | ||
| Q2 25 | 18.4% | 20.1% | ||
| Q1 25 | 12.9% | 15.9% | ||
| Q4 24 | 17.0% | 15.9% | ||
| Q3 24 | 15.3% | 18.0% | ||
| Q2 24 | 15.7% | 19.0% |
净利率DXCMMAS
| Q1 26 | 21.2% | 11.9% | ||
| Q4 25 | 21.2% | 9.2% | ||
| Q3 25 | 23.5% | 9.9% | ||
| Q2 25 | 15.5% | 13.2% | ||
| Q1 25 | 10.2% | 10.3% | ||
| Q4 24 | 13.6% | 10.0% | ||
| Q3 24 | 13.5% | 8.4% | ||
| Q2 24 | 14.3% | 12.3% |
每股收益（稀释后）DXCMMAS
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.81 | ||
| Q3 25 | $0.70 | $0.90 | ||
| Q2 25 | $0.45 | $1.28 | ||
| Q1 25 | $0.27 | $0.87 | ||
| Q4 24 | $0.37 | $0.85 | ||
| Q3 24 | $0.34 | $0.77 | ||
| Q2 24 | $0.35 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | $2.9B |
| 股东权益账面价值 | $2.7B | $27.0M |
| 总资产 | $6.3B | $5.2B |
| 负债/权益比越低杠杆越低 | — | 109.07× |
8季度趋势，按日历期对齐
现金及短期投资DXCMMAS
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $647.0M | ||
| Q3 25 | $1.8B | $559.0M | ||
| Q2 25 | $1.2B | $390.0M | ||
| Q1 25 | $904.9M | $377.0M | ||
| Q4 24 | $606.1M | $634.0M | ||
| Q3 24 | $621.2M | $646.0M | ||
| Q2 24 | $939.2M | $398.0M |
总债务DXCMMAS
| Q1 26 | — | $2.9B | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DXCMMAS
| Q1 26 | $2.7B | $27.0M | ||
| Q4 25 | $2.7B | $-185.0M | ||
| Q3 25 | $2.7B | $-78.0M | ||
| Q2 25 | $2.6B | $-84.0M | ||
| Q1 25 | $2.3B | $-254.0M | ||
| Q4 24 | $2.1B | $-279.0M | ||
| Q3 24 | $2.0B | $-88.0M | ||
| Q2 24 | $2.4B | $-26.0M |
总资产DXCMMAS
| Q1 26 | $6.3B | $5.2B | ||
| Q4 25 | $6.3B | $5.2B | ||
| Q3 25 | $7.5B | $5.3B | ||
| Q2 25 | $7.3B | $5.3B | ||
| Q1 25 | $6.8B | $5.1B | ||
| Q4 24 | $6.5B | $5.0B | ||
| Q3 24 | $6.4B | $5.3B | ||
| Q2 24 | $6.8B | $5.4B |
负债/权益比DXCMMAS
| Q1 26 | — | 109.07× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
